$MDLN · Medline Inc.
Medline Inc. filed an S-1 registering 60,000,000 Class A common shares to be sold by selling stockholders, with no proceeds to the company. Concurrently, Medline and Medline Holdings agreed to repurchase $200 million of Class A shares and Common Units directly from selling stockholders at the underwriter price (assumed $39.47 per equity interest, implying 5,067,128 repurchased interests). The offering is led by Goldman Sachs, Morgan Stanley, BofA Securities, and J.P. Morgan, with Blackstone Capital Markets and Carlyle as co-managers.
- 60,000,000 Class A shares offered by selling stockholders; company receives no proceeds.
- Concurrent $200 million repurchase of shares/Common Units at the underwriter price.
- At $39.47 per equity interest, repurchase equals 5,067,128 shares/Common Units.
- Underwriters hold 30-day option for up to 9,000,000 additional shares.
- Medline is the largest med-surg products provider, with 18% net sales CAGR since inception.
Extended-hours last trade $37.00, down 6.26% vs the $39.47 regular close, suggesting the secondary supply overhang pressured shares.
A $200 million concurrent buyback partially offsets a 60-million-share sponsor-led secondary, testing demand for Medline's float.
A large secondary offering by private-equity sponsors (Blackstone, Carlyle, H&F) and the Mills family signals continued post-IPO monetization in the med-surg distribution space.
Selling stockholders' 60M-share offering plus the 9M-share option creates substantial supply overhang; the repurchase is conditioned on the offering closing, while the offering is not conditioned on the repurchase.